Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 22, 2019 Off

Global Drug Discovery Market Growth, Trends, and Forecasts Report 2019-2024 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Drug Discovery Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…

March 22, 2019 Off

Dementia – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Dementia – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Dementia – Pipeline Review,…

LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
March 22, 2019 Off

LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology

By BusinessWire

– Takeda obtains rights to LCB’s ADC platfo–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research…

March 22, 2019 Off

Akoya Biosciences Launches Comprehensive Solution for High-Parameter Tissue Analysis

By BusinessWire

Commercial launch of CODEX® System and Phenoptics™ 2.0 provide the most complete suite of tools for tissue biomarker discovery and…

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
March 21, 2019 Off

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

By BusinessWire

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational…

Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019
March 21, 2019 Off

Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

By BusinessWire

NÎMES, France–(BUSINESS WIRE)–Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC – FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric…

March 21, 2019 Off

Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million

By BusinessWire

Preliminary Annual Revenue Increase by 2.7x Compared to Prior Year SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”)…

March 21, 2019 Off

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

By BusinessWire

CAMBRIDGE, England–(BUSINESS WIRE)–Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought…

Enzyvant to get RVT-801 available to Farber disease patients as quickly as possible after FDA’s nod
March 21, 2019 Off

Enzyvant to get RVT-801 available to Farber disease patients as quickly as possible after FDA’s nod

By Dino Mustafić

Enzyvant’s RVT-801, an investigational enzyme replacement therapy, was granted Rare Pediatric Disease and Fast Track designations by the FDA, the company said in a press release Thursday.

MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback
March 21, 2019 Off

MatriSys closer to begin testing MSB-01 for Atopic Dermatitis, afer FDA’s positive feedback

By Dino Mustafić

MatriSys Bioscience got positive feedback from the FDA on its planned initiation of clinical trials for MSB-01 under a U.S. IND for MatriSys’ lead microbiome-based candidate, MSB-01, for the treatment of Atopic Dermatitis (AD).

Posts pagination

Previous 1 … 3,339 3,340 3,341 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine